MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program
News Dec 12, 2008
MorphoSys AG has announced that its licensing partner, Centocor R&D Inc., has enrolled a patient in a Phase 2 clinical trial with a HuCAL-derived fully human antibody. A Phase 1 clinical trial using the same antibody in oncology patients was initiated in 2007 and is ongoing.
The new trial is in an immunology indication. This achievement marks the first antibody, developed with MorphoSys's core technology, to enter human clinical trials in a second indication with partners. The initiation of the Phase 2 trial and the IND in a new indication trigger clinical milestone payments to MorphoSys.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE